Please login to the form below

Not currently logged in

Sanofi-aventis Q1 hit by H1N1

Sanofi-aventis has seen its first-quarter financial results hit by lack of flu vaccine and generic competition

Sanofi-aventis (SA) has reported a 16.1 per cent fall in net income to €2.2bn at CER for the first quarter of 2011.

The company posted a 5.2 per cent decline in first-quarter sales to €7.8bn in 2011, including €569m of sales lost in 2011 due to generic competition,.

However, excluding A/H1N1 sales its first-quarter sales rose by 0.1 per cent.

The company said emerging markets sales increased by 14.6 per cent (excluding A/H1N1 sales) to €2.4bn, exceeding the US and Western Europe, and accounted for 30.7 per cent of group sales.

Christopher A Viehbacher, CEO, S-A, said: "This quarter, the year-on-year comparison must take into account the absence of non-recurring A/H1N1 sales. I'm particularly satisfied with the performance of our growth platforms which were up 15.5 per cent (excluding A/H1N1) and now represent almost 60 per cent of group sales; these businesses have compensated for the impact of generic competition on net sales and represent the future of our company."

S-A's EPS was €1.66, down 16.1 per cent at CER. Excluding A/H1N1 sales, the decrease in business EPS was limited to 6.0 per cent at CER.

28th April 2011


Featured jobs

Subscribe to our email news alerts


Add my company
Kantar Health

Kantar Health is a leading global healthcare consulting firm and trusted advisor to many of the world’s leading pharmaceutical, biotech,...

Latest intelligence

Waking the sleeping giant
The lights are coming on for healthcare delivery in Africa...
How to get rep buy-in for multi-channel
How do you manage a team who may be resistant to change?...
Blog: Digital therapeutics: within our reach?
Digital therapeutics is a hot topic right now. By using digital technology to manage, treat or even prevent chronic conditions, digital therapeutics is promising to revolutionise healthcare. But is this...